BioGeneration
•BioGeneration Ventures
•Blackfin Capital Partners
•Cat Bonds
•Closed Loop
•Closed Loop Partners
•CNBC
•Dezima
•Dodeka
•FCF III
•Forbes
•Forbion
•Fund IV
•ILS
•Incofin
•Insurance Linked Securities
•Jay Koh
•Life Sciences
•London
•Market Perspectives
•Micro Finance
•Osmosis
•The Lightsmith Group
•third fund
•TrueBridge
•Twelve
•Unovis
•Urs Ramseier
•Venture Capital
•Video
- August 18, 2014
Forbion announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m
August 18, 2014Read moreFor immediate release 5 August 2014 Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m  From early investment...
0 - July 3, 2014
Urs Ramseier, Twelve Chairman/CIO, interviewed by CNBC
July 3, 2014Read moreUrs Ramseier, chairman at Twelve Capital, says that the main benefit of catastrophe bonds is that they are “uncorrelated with other assets” and discusses...
- June 17, 2014
Gene therapy: A major therapeutic breakthrough uniQure – DIST 2013 – VIDEO
June 17, 2014Read moreSander van Deventer is partner at Forbion and on the board of uniQure. He was the second speaker a DIST 2013. He explained how new break-through...
- June 3, 2014
Twelve Capital issues the private Catastrophe Bond “Dodeka IV”
June 3, 2014Read moreTwelve Capital AG is pleased to announce the issuance of the private Catastrophe (“Cat”) Bond “Dodeka IV”. Dodeka IV is a USD 28m zero-coupon Cat...
- June 3, 2014
Forbion in zee met rijke families om nieuwe medicijnen te ontwikkelen
June 3, 2014Read moreArticle in the “Financieel Dagblad” Friday 23 May 2014. Click here to read.